CC
RNAM

Commodore Capital’s Avidity Biosciences RNAM Stock Holding History

Commodore Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-590,705
Closed -$9.07M – 31
2023
Q1 		$9.07M Hold
590,705
– – 1.38% 22
2022
Q4 		$13.1M Buy
+590,705
New +$8.81M 1.98% 21

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Commodore Capital's RNAM Position: Q2 2023 in Review

Commodore Capital sold out of Avidity Biosciences (RNAM) in Q2 2023, closing a stake of 590,705 shares — an estimated $9.07M sold.

Commodore Capital first reported a position in RNAM in Q4 2022 and held it in 2 quarters. The position peaked at $13.1M in Q4 2022. 143 funds tracked by Wall St. Rank hold RNAM as of Q2 2023.

  • Commodore Capital reported no remaining Avidity Biosciences position as of Q2 2023 after selling out during the quarter.
  • Commodore Capital sold 590,705 Avidity Biosciences shares in Q2 2023, an estimated $9.07M.
  • Commodore Capital first reported a position in Avidity Biosciences in Q4 2022 and held it in 2 quarters.
  • Commodore Capital's Avidity Biosciences position peaked at $13.1M in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2023.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.